Bristol-Myers Squibb withdraws European license application of nivolumab with ipilimumab for first-line treatment of advanced non-small cell lung cancer (NSCLC)

The report suggests the European Committee for Medicinal Products for Human Use determined a full assessment of the application was not possible following multiple protocol changes to the CheckMate-227 trial, which the company made in response to rapidly evolving data.


Biospace Inc.